Senseonics Holdings went into this report as a high growth, high expectation diabetes tech stock, and the market clearly liked what it saw. The share price jumped about 36% to US$7.02 the day after earnings, a big move for a medical device company still posting sizeable losses.

The headline is simple: strong revenue traction in continuous glucose monitoring and a sharp lift in gross margin grabbed investors’ attention, even though Senseonics reported a net loss of US$36.7 million for the quarter. The stock is now trading as if this revenue and margin story can keep building.

Is Senseonics Holdings suddenly priced for perfection after this 36% jump, or do the losses and rich P/S multiple still dominate the story? See how revenue…